Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24

Sci Rep. 2024 Oct 1;14(1):22861. doi: 10.1038/s41598-024-73822-w.

Abstract

Multiple myeloma (MM) is a common hematological malignancy, and its prognostic factors have been extensively studied. Progression of disease within 24 months (POD24) suggests a poor prognosis in many malignancies, but is rarely mentioned in MM. This study aimed to investigate the prognostic value of POD24 in MM and risk factors of POD24, and to evaluate the predictive value of existing MM prognostic models for POD24. The research retrospectively analyzed the clinical data of MM patients and found that the occurrence of POD24 is an independent prognostic factor affecting overall survival in MM, while non-transplantion and genetic abnormality are independent risk factors for the occurrence of POD24. The existing prognostic models are not effective in predicting POD24. Therefore, it's still necessary to explore a prognostic model that can predict POD24 more accurately.

Keywords: Multiple myeloma; POD24; Prognostic analysis; Prognostic factor; Prognostic model.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Disease Progression*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / mortality
  • Multiple Myeloma* / pathology
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Time Factors